Biotech4 hours ago
Volatile Outlook for Enlivex Therapeutics as Investors Await Clinical Catalysts
Enlivex Therapeutics stock attracts speculative biotech investors amid volatility, weak performance, and limited institutional coverage. Shares near $1.40–$1.50 reflect a yearlong decline of roughly 35–40 percent...